指南与共识鼻科

国际过敏与鼻科学共识声明:过敏性鼻炎-2023

International consensus statement on allergy and rhinology: Allergic rhinitis - 2023.
指南 / 共识 · Int Forum Allergy Rhinol · 2023-03-06

ICAR-过敏性鼻炎2023更新采用循证综述与推荐方法学,对144个过敏性鼻炎主题进行迭代同行评审与共识,涵盖10大内容领域,汇总证据等级并给出推荐摘要,为患者评估和治疗提供循证推荐。

要点

  • ICAR-过敏性鼻炎2023包含10大内容领域和144个主题。
  • 对各主题汇总证据等级,并考虑获益、危害和成本给出推荐摘要。
  • 更新对2018年原有主题进行审查和更新,新增超过40个主题。

核心结论

  • ICAR-过敏性鼻炎2023更新对过敏性鼻炎及当前可用证据进行了全面评估,这些证据构成了当前知识库及患者评估和治疗推荐的基础。

研究设计与样本

  • ICAR-过敏性鼻炎2023采用既定的循证综述与推荐(EBRR)方法学对每个主题单独评估,并进行逐步迭代同行评审和共识。
  • 最终文件汇总了10大内容领域和144个与过敏性鼻炎相关的独立主题的工作结果。

主要发现

  • ICAR-过敏性鼻炎2023包含10大内容领域和144个独立主题,较2018年文件新增超过40个主题。
  • 对相当一部分纳入主题,通过汇总文献中每项可用研究的证据水平,给出了汇总证据等级。
  • 对考虑诊断或治疗干预的主题,呈现推荐摘要,该摘要考虑汇总证据等级、获益、危害和成本。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR-Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR-Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence-based findings and recommendation from the full document. METHODS: ICAR-Allergic Rhinitis 2023 employed established evidence-based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. RESULTS: ICAR-Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. CONCLUSION: The ICAR-Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Wise SK, Damask C, Roland LT, et al. International consensus statement on allergy and rhinology: Allergic rhinitis - 2023. Int Forum Allergy Rhinol. 2023. PMID: 36878860. doi:10.1002/alr.23090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。